Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 5/20 | 0.52 |
| ▸ | MME | P08473 | 4/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | CHRND | Q07001 | 4/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG | P07510 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644411 | 0.96 | MME (0.52) | ENPEPMMEACECPA1ACE2 | |
| SCHEMBL29822475 | 0.93 | MME (0.56) | ENPEPMMEACECPA1ACE2 | |
| SCHEMBL29602654 | 0.90 | MME (0.63) | MMEACECHRNDCHRNA1CHRNG | |
| SCHEMBL29350849 | 0.90 | MME (0.63) | MMEACECHRNDCHRNA1CHRNG | |
| SCHEMBL29603463 | 0.90 | MME (0.63) | MMEACECHRNDCHRNA1CHRNG | |
| SCHEMBL13588078 | 0.90 | MME (0.63) | MMEACECHRNDCHRNA1CHRNG | |
| SCHEMBL29349607 | 0.89 | MME (0.59) | MMEACECPA1ACE2 | |
| SCHEMBL30900762 | 0.89 | MME (0.59) | MMEACECPA1ACE2 | |
| SCHEMBL3459805 | 0.87 | ACE (0.60) | MMEACECPA1ACE2CHRND | |
| SCHEMBL7110125 | 0.87 | ACE (0.60) | MMEACECPA1ACE2CHRND |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121031-A1 | MASKED FLUOROGENIC COMPOUNDS AND METHODS OF USING THE SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121031-A1 | MASKED FLUOROGENIC COMPOUNDS AND METHODS OF USING THE SAME | HNRNPAB, HAVCR2, APBA1 | ENPEP 178/4885MME 163/4885ACE 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.